{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T12:10:40Z","timestamp":1780920640506,"version":"3.54.1"},"reference-count":69,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T00:00:00Z","timestamp":1770336000000},"content-version":"vor","delay-in-days":36,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100018786","name":"Al-Zaytoonah University of Jordan","doi-asserted-by":"publisher","award":["2025\\u22122024\/06\/28"],"award-info":[{"award-number":["2025\\u22122024\/06\/28"]}],"id":[{"id":"10.13039\/501100018786","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018786","name":"Al-Zaytoonah University of Jordan","doi-asserted-by":"publisher","award":["27\/06\/2024-2025"],"award-info":[{"award-number":["27\/06\/2024-2025"]}],"id":[{"id":"10.13039\/501100018786","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment and Research Communications"],"published-print":{"date-parts":[[2026]]},"DOI":"10.1016\/j.ctarc.2026.101133","type":"journal-article","created":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T16:48:38Z","timestamp":1770655718000},"page":"101133","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Synergistic cytotoxic effect of doxorubicin and bortezomib on lung cancer cell lines using 2D and 3D models"],"prefix":"10.1016","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9451-279X","authenticated-orcid":false,"given":"Mohammad","family":"Alwahsh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0856-5618","authenticated-orcid":false,"given":"Osama H.","family":"Abusara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alia Abu","family":"Zaid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-8554-3482","authenticated-orcid":false,"given":"Aya","family":"Hasan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4672-3303","authenticated-orcid":false,"given":"Lama","family":"Hamadneh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosemarie","family":"Marchan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctarc.2026.101133_bib0001","series-title":"Lung cancer","article-title":"International-Agency-for-Research-on-Cancer","year":"2022"},{"key":"10.1016\/j.ctarc.2026.101133_bib0002","series-title":"Paper Presented at the Seminars in Cancer Biology","article-title":"Current knowledge of small cell lung cancer transformation from non-small cell lung cancer","author":"Giaccone","year":"2023"},{"issue":"18","key":"10.1016\/j.ctarc.2026.101133_bib0003","doi-asserted-by":"crossref","first-page":"2883","DOI":"10.1002\/cncr.28749","article-title":"US lung cancer trends by histologic type","volume":"120","author":"Lewis","year":"2014","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.ctarc.2026.101133_bib0004","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.ccm.2019.11.001","article-title":"Lung cancer pathology: current concepts","volume":"41","author":"Travis","year":"2020","journal-title":"Clin. Chest Med."},{"issue":"1","key":"10.1016\/j.ctarc.2026.101133_bib0005","doi-asserted-by":"crossref","first-page":"99","DOI":"10.6004\/jnccn.2013.0012","article-title":"Modern staging of small cell lung cancer","volume":"11","author":"Kalemkerian","year":"2013","journal-title":"J. Natl Compreh. Cancer Network"},{"issue":"9","key":"10.1016\/j.ctarc.2026.101133_bib0006","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1038\/nrclinonc.2017.71","article-title":"Unravelling the biology of SCLC: implications for therapy","volume":"14","author":"Sabari","year":"2017","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"21","key":"10.1016\/j.ctarc.2026.101133_bib0008","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1001\/jama.2025.0560","article-title":"Small cell lung cancer: a review","volume":"333","author":"Kim","year":"2025","journal-title":"JAMa"},{"key":"10.1016\/j.ctarc.2026.101133_bib0009","series-title":"Small Cell Lung Cancer Treatment (PDQ\u00ae)\u2013Health Professional Version","year":"2025"},{"issue":"1","key":"10.1016\/j.ctarc.2026.101133_bib0010","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s00408-025-00801-x","article-title":"Update 2025: management of non\u2011small-cell lung cancer","volume":"203","author":"Jeon","year":"2025","journal-title":"Lung"},{"issue":"25","key":"10.1016\/j.ctarc.2026.101133_bib0011","doi-asserted-by":"crossref","first-page":"3267","DOI":"10.2174\/092986709788803312","article-title":"Doxorubicin: the good, the bad and the ugly effect","volume":"16","author":"Carvalho","year":"2009","journal-title":"Curr. Med. Chem."},{"issue":"4","key":"10.1016\/j.ctarc.2026.101133_bib0012","doi-asserted-by":"crossref","DOI":"10.3390\/cells12040659","article-title":"Doxorubicin-an agent with multiple mechanisms of anticancer activity","volume":"12","author":"Kciuk","year":"2023","journal-title":"Cells"},{"issue":"3","key":"10.1016\/j.ctarc.2026.101133_bib0013","doi-asserted-by":"crossref","first-page":"271","DOI":"10.2147\/tcrm.2006.2.3.271","article-title":"Bortezomib (Velcade\u2122) in the treatment of multiple myeloma","volume":"2","author":"Field-Smith","year":"2006","journal-title":"Ther. Clin. Risk Manag."},{"issue":"18","key":"10.1016\/j.ctarc.2026.101133_bib0014","doi-asserted-by":"crossref","first-page":"5291","DOI":"10.1158\/1078-0432.CCR-07-0871","article-title":"Bortezomib for the treatment of mantle cell lymphoma","volume":"13","author":"Kane","year":"2007","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.ctarc.2026.101133_bib0015","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1007\/s11033-024-09669-1","article-title":"Cytotoxic and molecular differences of anticancer agents on 2D and 3D cell culture","volume":"51","author":"Alwahsh","year":"2024","journal-title":"Mol. Biol. Rep."},{"key":"10.1016\/j.ctarc.2026.101133_bib0016","first-page":"146","article-title":"Bortezomib advanced mechanisms of action in multiple myeloma, solid and liquid tumors along with its novel therapeutic applications","volume":"22","author":"Alwahsh","year":"2023","journal-title":"EXCLI J."},{"issue":"5","key":"10.1016\/j.ctarc.2026.101133_bib0017","doi-asserted-by":"crossref","first-page":"3179","DOI":"10.3892\/ol.2016.4340","article-title":"Bortezomib and etoposide combinations exert synergistic effects on the human prostate cancer cell line PC-3","volume":"11","author":"Aras","year":"2016","journal-title":"Oncol. Lett."},{"issue":"2","key":"10.1016\/j.ctarc.2026.101133_bib0018","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s13402-024-01001-0","article-title":"The long non-coding RNA NEAT1 contributes to aberrant STAT3 signaling in pancreatic cancer and is regulated by a metalloprotease-disintegrin ADAM8\/miR-181a-5p axis","volume":"48","author":"Gao","year":"2025","journal-title":"Cell Oncol. (Dordr)"},{"key":"10.1016\/j.ctarc.2026.101133_bib0019","doi-asserted-by":"crossref","DOI":"10.1016\/j.fct.2025.115271","article-title":"The extracts from centaurea species abolished the cytotoxic effects of doxorubicin on breast cancer cell line - MCF-7 and bortezomib on prostate cancer cell line- PC3","volume":"197","author":"J\u00f3zefczyk","year":"2025","journal-title":"Food Chem. Toxicol."},{"issue":"6","key":"10.1016\/j.ctarc.2026.101133_bib0020","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1007\/s12032-021-01509-7","article-title":"Treating MCF7 breast cancer cell with proteasome inhibitor Bortezomib restores apoptotic factors and sensitizes cell to Docetaxel","volume":"38","author":"Mehdizadeh","year":"2021","journal-title":"Med. Oncol."},{"issue":"4","key":"10.1016\/j.ctarc.2026.101133_bib0021","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1007\/s00280-004-0811-4","article-title":"Effects of the proteasome inhibitor bortezomib alone and in combination with chemotherapy in the A549 non-small-cell lung cancer cell line","volume":"54","author":"Mortenson","year":"2004","journal-title":"Cancer Chemother Pharmacol."},{"issue":"5","key":"10.1016\/j.ctarc.2026.101133_bib0022","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1021\/acs.molpharmaceut.4c01283","article-title":"Nanoparticle albumin-bound bortezomib: enhanced antitumor efficacy and tumor accumulation in breast cancer therapy","volume":"22","author":"Saremi Poor","year":"2025","journal-title":"Mol. Pharm."},{"issue":"1","key":"10.1016\/j.ctarc.2026.101133_bib0023","doi-asserted-by":"crossref","DOI":"10.1111\/jcmm.70254","article-title":"Comparative analysis of acquired resistance to bortezomib in prostate cancer cells using proteomic and bioinformatic tools","volume":"29","author":"Seker","year":"2025","journal-title":"J. Cell Mol. Med."},{"issue":"7","key":"10.1016\/j.ctarc.2026.101133_bib0024","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1093\/carcin\/bgq097","article-title":"G(alpha)12\/13 inhibition enhances the anticancer effect of bortezomib through PSMB5 downregulation","volume":"31","author":"Yang","year":"2010","journal-title":"Carcinogenesis"},{"issue":"Pt 4","key":"10.1016\/j.ctarc.2026.101133_bib0025","article-title":"Gelatin-dopamine-based dual-responsive nanogels for tumor-targeted bortezomib delivery: minimizing systemic toxicity and enhancing breast cancer therapy","volume":"318","author":"Zheng","year":"2025","journal-title":"Int. J. Biol. Macromol."},{"issue":"6","key":"10.1016\/j.ctarc.2026.101133_bib0026","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1111\/jcmm.12279","article-title":"Proteasome inhibitors\u2013molecular basis and current perspectives in multiple myeloma","volume":"18","author":"Kubiczkova","year":"2014","journal-title":"J. Cell. Mol. Med."},{"issue":"1","key":"10.1016\/j.ctarc.2026.101133_bib0027","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1186\/s12885-019-5939-z","article-title":"Mechanisms of doxorubicin-induced drug resistance and drug resistant tumour growth in a murine breast tumour model","volume":"19","author":"Christowitz","year":"2019","journal-title":"BMC. Cancer"},{"issue":"7","key":"10.1016\/j.ctarc.2026.101133_bib0028","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.3390\/cells10071657","article-title":"Transcending toward advanced 3D-cell culture modalities: a review about an emerging paradigm in translational oncology","volume":"10","author":"Farhat","year":"2021","journal-title":"Cells"},{"issue":"6","key":"10.1016\/j.ctarc.2026.101133_bib0029","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0324930","article-title":"Thionated levofloxacin derivative: potential repurposing for cancer treatment and synergism with doxorubicin on doxorubicin-resistant lung cancer cells","volume":"20","author":"Abumansour","year":"2025","journal-title":"PLoS. One"},{"issue":"9","key":"10.1016\/j.ctarc.2026.101133_bib0030","doi-asserted-by":"crossref","first-page":"6963","DOI":"10.1007\/s00210-024-03075-x","article-title":"Biological evaluation of levofloxacin and its thionated derivatives: antioxidant activity, aldehyde dehydrogenase enzyme inhibition, and cytotoxicity on A549 cell line","volume":"397","author":"Abumansour","year":"2024","journal-title":"Naunyn Schmiedebergs Arch. Pharmacol."},{"key":"10.1016\/j.ctarc.2026.101133_bib0031","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.ejmech.2017.05.053","article-title":"Pentapeptides for the treatment of small cell lung cancer: optimisation by Nind-alkyl modification of the tryptophan side chain","volume":"137","author":"Haitham Abusara","year":"2017","journal-title":"Eur. J. Med. Chem."},{"issue":"3","key":"10.1016\/j.ctarc.2026.101133_bib0032","first-page":"71","article-title":"An improvement of the 2\u02c6 (\u2013delta delta CT) method for quantitative real-time polymerase chain reaction data analysis","volume":"3","author":"Rao","year":"2013","journal-title":"Biostat. Bioinforma Biomath."},{"key":"10.1016\/j.ctarc.2026.101133_bib0033","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/j.ijbiomac.2021.07.185","article-title":"Non-cell adhesive hexanoyl glycol chitosan hydrogels for stable and efficient formation of 3D cell spheroids with tunable size and density","volume":"187","author":"Jang","year":"2021","journal-title":"Int. J. Biol. Macromol."},{"issue":"22","key":"10.1016\/j.ctarc.2026.101133_bib0034","doi-asserted-by":"crossref","DOI":"10.3390\/ijms222212200","article-title":"3D cell culture systems: tumor application, advantages, and disadvantages","volume":"22","author":"Habanjar","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"8","key":"10.1016\/j.ctarc.2026.101133_bib0035","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.3390\/pharmaceutics14081722","article-title":"Beyond formulation: contributions of nanotechnology for translation of anticancer natural products into new drugs","volume":"14","author":"Miguel","year":"2022","journal-title":"Pharmaceutics"},{"issue":"7","key":"10.1016\/j.ctarc.2026.101133_bib0036","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1097\/FPC.0b013e32833ffb56","article-title":"Doxorubicin pathways: pharmacodynamics and adverse effects","volume":"21","author":"Thorn","year":"2011","journal-title":"Pharmacogenet. Genom."},{"key":"10.1016\/j.ctarc.2026.101133_bib0037","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.jconrel.2022.10.022","article-title":"Tailoring carrier-free nanocombo of small-molecule prodrug for combinational cancer therapy","volume":"352","author":"Li","year":"2022","journal-title":"J. Controlled Rel."},{"issue":"17\u201318","key":"10.1016\/j.ctarc.2026.101133_bib0038","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1016\/j.drudis.2012.05.010","article-title":"Nanotechnology-based combinational drug delivery: an emerging approach for cancer therapy","volume":"17","author":"Parhi","year":"2012","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.ctarc.2026.101133_bib0039","series-title":"H69","year":"2025"},{"key":"10.1016\/j.ctarc.2026.101133_bib0040","series-title":"H69AR","year":"2025"},{"key":"10.1016\/j.ctarc.2026.101133_bib0041","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.ejmech.2017.05.053","article-title":"Pentapeptides for the treatment of small cell lung cancer: optimisation by Nind-alkyl modification of the tryptophan side chain","volume":"137","author":"Abusara","year":"2017","journal-title":"Eur. J. Med. Chem."},{"issue":"8","key":"10.1016\/j.ctarc.2026.101133_bib0042","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.1002\/2211-5463.13230","article-title":"Resveratrol reduces drug resistance of SCLC cells by suppressing the inflammatory microenvironment and the STAT3\/VEGF pathway","volume":"11","author":"Hou","year":"2021","journal-title":"FEBS. Open. Bio"},{"issue":"12","key":"10.1016\/j.ctarc.2026.101133_bib0043","doi-asserted-by":"crossref","first-page":"6956","DOI":"10.21037\/tcr-2024-2379","article-title":"PTPMT1 inhibition induces apoptosis and growth arrest of human SCLC cells by disrupting mitochondrial metabolism","volume":"13","author":"Liu","year":"2024","journal-title":"Transl. Cancer Res."},{"issue":"3","key":"10.1016\/j.ctarc.2026.101133_bib0044","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1039\/C6MD00691D","article-title":"N-tert-prenylation of the indole ring improves the cytotoxicity of a short antagonist G analogue against small cell lung cancer","volume":"8","author":"Offerman","year":"2017","journal-title":"Medchemcomm."},{"issue":"2","key":"10.1016\/j.ctarc.2026.101133_bib0045","doi-asserted-by":"crossref","first-page":"170","DOI":"10.3390\/ph16020170","article-title":"Castasterone, a plant steroid hormone, affects human small-cell lung cancer cells and reverses multi-drug resistance","volume":"16","author":"Sadava","year":"2023","journal-title":"Pharmaceuticals"},{"issue":"16","key":"10.1016\/j.ctarc.2026.101133_bib0046","doi-asserted-by":"crossref","DOI":"10.1002\/cmdc.202500260","article-title":"Synthesis and characterization of sulfonamide-imidazole hybrids with In vitro antiproliferative activity against anthracycline-sensitive and resistant H69 small cell lung cancer cells","volume":"20","author":"Vainauskas","year":"2025","journal-title":"ChemMedChem."},{"issue":"15","key":"10.1016\/j.ctarc.2026.101133_bib0047","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.3390\/cells12151980","article-title":"A novel NCI-H69AR drug-resistant small-cell lung cancer mini-tumor model for anti-cancer treatment screening","volume":"12","author":"van Niekerk","year":"2023","journal-title":"Cells"},{"key":"10.1016\/j.ctarc.2026.101133_bib0048","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2023.123392","article-title":"Identifying synergistic combinations of Doxorubicin-loaded polyquercetin nanoparticles and natural products: implications for breast cancer therapy","volume":"645","author":"Sunoqrot","year":"2023","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ctarc.2026.101133_bib0049","doi-asserted-by":"crossref","first-page":"7207","DOI":"10.2147\/OTT.S112566","article-title":"Monitoring the effects of doxorubicin on 3D-spheroid tumor cells in real-time","author":"Baek","year":"2016","journal-title":"Onco Targets Ther."},{"issue":"6","key":"10.1016\/j.ctarc.2026.101133_bib0050","doi-asserted-by":"crossref","first-page":"4777","DOI":"10.1007\/s11033-022-07329-w","article-title":"Proteasome inhibitor immunotherapy for the epithelial to mesenchymal transition: assessing the A549 lung cancer cell microenvironment and the role of M1, M2a and M2c 'hydrocortisone-polarised' macrophages","volume":"49","author":"Eng\u00fcr-\u00d6zt\u00fcrk","year":"2022","journal-title":"Mol. Biol. Rep."},{"issue":"2","key":"10.1016\/j.ctarc.2026.101133_bib0051","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s10544-014-9918-5","article-title":"Alginate core-shell beads for simplified three-dimensional tumor spheroid culture and drug screening","volume":"17","author":"Yu","year":"2015","journal-title":"Biomed. Microdevices"},{"issue":"1","key":"10.1016\/j.ctarc.2026.101133_bib0052","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1158\/1078-0432.CCR-16-0529","article-title":"Combination of imatinib mesylate and AKT inhibitor provides synergistic effects in preclinical study of gastrointestinal stromal tumor","volume":"23","author":"Zook","year":"2017","journal-title":"Clin. Cancer Res."},{"issue":"10","key":"10.1016\/j.ctarc.2026.101133_bib0053","first-page":"2594","article-title":"Multidrug resistance in a human small cell lung cancer cell line selected in adriamycin","volume":"47","author":"Mirski","year":"1987","journal-title":"Cancer Res."},{"issue":"67","key":"10.1016\/j.ctarc.2026.101133_bib0054","first-page":"471","article-title":"Advances in the understanding of mechanisms and therapeutic use of bortezomib","volume":"12","author":"Mujtaba","year":"2011","journal-title":"Discov. Med."},{"issue":"1","key":"10.1016\/j.ctarc.2026.101133_bib0055","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s00280-005-0135-z","article-title":"Bortezomib interactions with chemotherapy agents in acute leukemia in vitro","volume":"58","author":"Horton","year":"2006","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"4","key":"10.1016\/j.ctarc.2026.101133_bib0056","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.gpb.2016.11.005","article-title":"Exploitation of gene expression and cancer biomarkers in paving the path to era of personalized medicine","volume":"15","author":"Kamel","year":"2017","journal-title":"Genom. Proteom. Bioinform."},{"issue":"5","key":"10.1016\/j.ctarc.2026.101133_bib0057","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/nrc3721","article-title":"Principles and methods of integrative genomic analyses in cancer","volume":"14","author":"Kristensen","year":"2014","journal-title":"Nat. Rev. Cancer"},{"issue":"3","key":"10.1016\/j.ctarc.2026.101133_bib0058","doi-asserted-by":"crossref","first-page":"417","DOI":"10.3390\/life15030417","article-title":"Antitumor effects of quercetin and luteolin in A375 cutaneous melanoma cell line are mediated by upregulation of P-ERK, c-Myc, and the upstream GPER","volume":"15","author":"Hussein","year":"2025","journal-title":"Life"},{"issue":"12","key":"10.1016\/j.ctarc.2026.101133_bib0059","doi-asserted-by":"crossref","DOI":"10.18632\/oncotarget.15690","article-title":"The genetic variants in the PTEN\/PI3K\/AKT pathway predict susceptibility and CE (A) F chemotherapy response to breast cancer and clinical outcomes","volume":"8","author":"Li","year":"2017","journal-title":"Oncotarget"},{"issue":"3","key":"10.1016\/j.ctarc.2026.101133_bib0060","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1158\/1078-0432.CCR-21-1943","article-title":"Activation of PI3K\/AKT pathway is a potential mechanism of treatment resistance in small cell lung cancer","volume":"28","author":"Jin","year":"2022","journal-title":"Clin. Cancer Res."},{"issue":"48","key":"10.1016\/j.ctarc.2026.101133_bib0061","doi-asserted-by":"crossref","first-page":"11817","DOI":"10.1021\/jf404092f","article-title":"Curcumin suppresses doxorubicin-induced epithelial\u2013mesenchymal transition via the inhibition of TGF-\u03b2 and PI3K\/AKT signaling pathways in triple-negative breast cancer cells","volume":"61","author":"Chen","year":"2013","journal-title":"J. Agric. Food Chem."},{"key":"10.1016\/j.ctarc.2026.101133_bib0062","doi-asserted-by":"crossref","first-page":"vi223","DOI":"10.1093\/annonc\/mdw371.51","article-title":"PIK3CA mutations up-regulate Akt expression and confer aggressive tumor biology in gastric cancer","volume":"27","author":"Lee","year":"2016","journal-title":"Ann. Oncol."},{"issue":"9","key":"10.1016\/j.ctarc.2026.101133_bib0063","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1038\/s41580-018-0015-0","article-title":"The functions and regulation of the PTEN tumour suppressor: new modes and prospects","volume":"19","author":"Lee","year":"2018","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"3","key":"10.1016\/j.ctarc.2026.101133_bib0064","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a036152","article-title":"Structural mechanisms of PTEN regulation","volume":"10","author":"Masson","year":"2020","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"10.1016\/j.ctarc.2026.101133_bib0065","series-title":"Paper presented at the Seminars in Cancer Biology","article-title":"Oncogenic signaling pathways associated with immune evasion and resistance to immune checkpoint inhibitors in cancer","author":"Kobayashi","year":"2020"},{"issue":"7","key":"10.1016\/j.ctarc.2026.101133_bib0066","doi-asserted-by":"crossref","first-page":"719","DOI":"10.3390\/genes11070719","article-title":"PTEN alterations and their role in cancer management: are we making headway on precision medicine?","volume":"11","author":"Fusco","year":"2020","journal-title":"Genes"},{"issue":"1","key":"10.1016\/j.ctarc.2026.101133_bib0067","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1146\/annurev-pathmechdis-051222-115023","article-title":"Apoptosis in cancer biology and therapy","volume":"20","author":"Moyer","year":"2025","journal-title":"Annu Rev. Pathol."},{"issue":"8","key":"10.1016\/j.ctarc.2026.101133_bib0068","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1038\/s41423-025-01310-w","article-title":"NF-\u03bab in inflammation and cancer","volume":"22","author":"Mao","year":"2025","journal-title":"Cell. Mol. Immunol."},{"issue":"4","key":"10.1016\/j.ctarc.2026.101133_bib0069","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1007\/s12288-024-01742-w","article-title":"MiR-34c-5p inhibition affects bax\/Bcl2 expression and reverses bortezomib resistance in multiple myeloma cells","volume":"40","author":"Matour","year":"2024","journal-title":"Indian J. Hematol. Blood Transf."},{"issue":"2","key":"10.1016\/j.ctarc.2026.101133_bib0070","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1158\/1541-7786.MCR-10-0368","article-title":"Bortezomib induces nuclear translocation of i\u03bab\u03b1 resulting in gene-specific suppression of NF-\u03bab\u2013dependent transcription and induction of apoptosis in CTCL","volume":"9","author":"Juvekar","year":"2011","journal-title":"Mol. Cancer Res."}],"container-title":["Cancer Treatment and Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294226000444?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294226000444?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T11:42:14Z","timestamp":1780918934000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468294226000444"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":69,"alternative-id":["S2468294226000444"],"URL":"https:\/\/doi.org\/10.1016\/j.ctarc.2026.101133","relation":{},"ISSN":["2468-2942"],"issn-type":[{"value":"2468-2942","type":"print"}],"subject":[],"published":{"date-parts":[[2026]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Synergistic cytotoxic effect of doxorubicin and bortezomib on lung cancer cell lines using 2D and 3D models","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment and Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctarc.2026.101133","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101133"}}